Stock RNAC CARTESIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Real-time Estimate Cboe BZX
Other stock markets
 03:22:30 2024-06-04 pm EDT 		5-day change 1st Jan Change
36.28 USD +0.78% Intraday chart for Cartesian Therapeutics, Inc. +28.31% +75.32%
12:52pm Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target MT
May. 24 Mizuho Securities Starts Cartesian Therapeutics With Buy Rating MT

Evolution of the average Target Price on Cartesian Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6c820aff42edc7a82f.sWEn4_CcHbpPUEQF353sffZDgNvrGR_beNwwfqisYLg.wRZXsr_eUcMqICkouq6tHLd67IGzclW8QLl_P96bJc7yF1Wrwe97zSE5HQ~1ddb1407c94e36734cea4df637eb31c6

Analyst Recommendations on Cartesian Therapeutics, Inc.

Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target MT
Mizuho Securities Starts Cartesian Therapeutics With Buy Rating MT
Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target MT
Mizuho Trims Price Target on Selecta Biosciences to $3 From $4, Maintains Buy Rating MT
Needham Adjusts Price Target on Selecta Biosciences to $4 From $5, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Selecta Biosciences to $5 From $4, Maintains Buy Rating MT
Mizuho Securities Adjusts Selecta Biosciences Price Target to $4 From $5, Maintains Buy Rating MT
Canaccord Genuity Adjusts Selecta Biosciences Price Target to $9 From $10, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on Selecta Biosciences to $4 From $6, Reiterates Buy Rating MT
Needham Adjusts Price Target on Selecta Biosciences to $5 From $6, Reiterates Buy Rating MT
SVB Securities Initiates Selecta Biosciences at Outperform With $7 Price Target MT
SELECTA BIOSCIENCES : BTIG Starts Selecta Biosciences at Buy With $10 Price Target MT
SELECTA BIOSCIENCES : William Blair Upgrades Selecta Biosciences to Outperform from Market Perform MT
SELECTA BIOSCIENCES : Mizuho Upgrades Selecta Biosciences to Buy From Neutral, Adjusts Price Target to $8 From $2.50 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36 USD
Average target price
42.6 USD
Spread / Average Target
+18.33%
High Price Target
54 USD
Spread / Highest target
+50.00%
Low Price Target
38 USD
Spread / Lowest Target
+5.56%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cartesian Therapeutics, Inc.

Mizuho Securities
Leerink Partners
Needham & Co.
HC Wainwright
Canaccord Genuity
SVB Securities LLC
BTIG
William Blair & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RNAC Stock
  4. Consensus Cartesian Therapeutics, Inc.